Skip to Content
Merck

AB16661

Anti-PARP Poly ADP-ribose Polymerase-1 Antibody

serum, Chemicon®

Synonym(s):

Poly [ADP-ribose] polymerase 1, PARP-1, NAD(+) ADP-ribosyltransferase 1, ADPRT 1, Poly[ADP-ribose] synthase 1, ARTD1

Sign In to View Organizational & Contract Pricing.

Select a Size

All Photos(1)

About This Item

UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702

Product Name

Anti-PARP Poly ADP-ribose Polymerase-1 Antibody, serum, Chemicon®

biological source

rabbit

conjugate

unconjugated

antibody form

serum

antibody product type

primary antibodies

clone

polyclonal

species reactivity

rat, human, bovine, mouse

manufacturer/tradename

Chemicon®

technique(s)

ELISA: suitable
western blot: suitable

NCBI accession no.

NM_001618.3

UniProt accession no.

P09874

shipped in

dry ice

target post-translational modification

unmodified

Quality Level

100

Gene Information

bovine ... Parp1(286764)
human ... PARP1(142)
mouse ... Parp1(11545)
rat ... Parp1(25591)

Application

Research Category
Apoptosis & Cancer

Metabolism
Research Sub Category
Apoptosis - Additional

Enzymes & Biochemistry
This Anti-PARP Poly ADP-ribose Polymerase-1 Antibody is validated for use in ELISA, WB for the detection of PARP Poly ADP-ribose Polymerase-1.
Western blot: 1:500 using alkaline phosphatase.

ELISA

Optimal working dilutions must be determined by end user.

Biochem/physiol Actions

Recognizes 116 kDa PARP-1 and the 85 kDa apoptosis-related cleavage fragment.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Immunogen

Synthetic peptide based on the sequence from the C-terminal portion of the bovine PARP automodification domain (amino acids 509-524) conjugated to a carrier.

Other Notes

Replaces: 04-575; 04-576

Physical form

Antiserum containing 0.05% sodium azide. Liquid containing 0.05% sodium azide.

Preparation Note

Maintain frozen at -20°C in undiluted aliquots for up to 12 months.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.

Storage Class

10 - Combustible liquids

wgk

WGK 1

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Lauren K Jillson et al.
Molecular cancer research : MCR, 19(7), 1123-1136 (2021-04-14)
Prostate cancer genomic subtypes that stratify aggressive disease and inform treatment decisions at the primary stage are currently limited. Previously, we functionally validated an aggressive subtype present in 15% of prostate cancer characterized by dual deletion of MAP3K7 and CHD1.
Kwang Il Park et al.
Oncology letters, 13(4), 2521-2530 (2017-04-30)
Lonicera japonica Thunb. (L. japonica T.) has historically been used in Korean herbal medicine due to its anticancer and protective effects on the respiratory system. In the present study, the polyphenolic compounds in L. japonica T. were investigated using high-performance
Marlena Zyśk et al.
International journal of molecular sciences, 21(22) (2020-11-18)
The N-acetylaspartate network begins in neurons with N-acetylaspartate production catalyzed by aspartate N-acetyltransferase from acetyl-CoA and aspartate. Clinical studies reported a significant depletion in N-acetylaspartate brain level in type 1 diabetic patients. The main goal of this study was to
Hypermethylated in cancer 1 (HIC1), a tumor suppressor gene epigenetically deregulated in hyperparathyroid tumors by histone H3 lysine modification.
Svedlund, J; Koskinen Edblom, S; Marquez, VE; ?kerstrom, G; Bjorklund, P; Westin, G
The Journal of clinical endocrinology and metabolism null
Jessica Svedlund et al.
Endocrine-related cancer, 21(2), 231-239 (2013-12-03)
Primary hyperparathyroidism (pHPT) resulting from parathyroid tumors is a common endocrine disorder with incompletely understood etiology. In renal failure, secondary hyperparathyroidism (sHPT) occurs with multiple tumor development as a result of calcium and vitamin D regulatory disturbance. The aim of
View All Related Papers

Global Trade Item Number

SKUGTIN
AB1666104053252320569

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service